Qualitative assessment of von Willebrand factor (vWF) in cirrhotics following repeated doses of desmopressin acetate.
Qualitative abnormalities in von Willebrand Factor (vWF) in patients with cirrhosis have been little studied with contrasting results. We used crossed immunoelectrophoresis (2-DIE) and multimeric analysis of vWF in eight patients with stable hepatic cirrhosis to evaluate abnormalities in vWF before and 1 h following intravenous administration of three doses of desmopressin acetate (0.3 micrograms/kg) given at baseline, 4 and 24 h. We thought that qualitative abnormalities might be more easily detected following desmopressin as this is known to release vWF from storage sites. There was an increased electrophoretic mobility on 2-DIE in all patients with no change following desmopressin. The multimeric analysis did not show an increase in lower molecular weight multimers, but showed a statistically significant increase in higher molecular weight multimers following desmopressin (P less than 0.02). These results suggest that the vWF of cirrhotics has an abnormal charge (not altered by release following desmopressin) which would explain the increased electrophoretic mobility on 2-DIE with a normal pattern of lower molecular weight multimers using multimeric analysis.
Cardin
F
F
Hepatobiliary and Liver Transplantation Unit, Royal Free Hospital, London, UK.
Taylor
L
L
Hutton
R
R
McIntyre
N
N
Kernoff
P
P
Burroughs
A K
AK
D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage; D005169:Factor VIII / Q000378:metabolism; D006801:Humans; D007123:Immunoelectrophoresis, Two-Dimensional; D008103:Liver Cirrhosis / Q000097:blood*; D046911:Macromolecular Substances; D014841:von Willebrand Factor / Q000378:metabolism*
D046911:Macromolecular Substances; D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin